ABY 035Alternative Names: ABY-035; AFB-035
Latest Information Update: 27 Feb 2016
At a glance
- Originator Affibody
- Class Anti-inflammatories
- Mechanism of Action Interleukin-17 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Psoriasis
- Preclinical Inflammation
Most Recent Events
- 01 Feb 2016 Phase-I clinical trials in Psoriasis in United Kingdom (SC and IV) (NCT02690142)